Search
Search Results
-
Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass
BackgroundUnfractionated heparin (UFH) is commonly used during cardiac surgery with a cardiopulmonary bypass to prevent blood clotting. However,...
-
Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin
Voclosporin is an approved option for the long-term treatment of lupus nephritis. We aimed to provide a narrative review of the pharmacokinetics and...
-
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers
Background and ObjectiveAberrant accumulation of glycosphingolipids (GSLs) in the lysosome leads to GSL storage diseases. Glucosylceramide synthase...
-
Cepharanthine synergistically promotes methylprednisolone pharmacodynamics against human peripheral blood mononuclear cells possibly via regulation of P-glycoprotein/glucocorticoid receptor translocation
BackgroundCepharanthin ® alone or in combination with glucocorticoid (GC) has been used to treat chronic immune thrombocytopenia (ITP) since the...
-
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal...
-
Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir
The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however,...
-
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
Background and ObjectiveRuxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of...
-
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
IntroductionThe terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the...
-
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
BackgroundBimagrumab is a human monoclonal antibody binding to the activin type II receptor with therapeutic potential in conditions of muscle...
-
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of ovarian, breast,...
-
Safety, Pharmacokinetics, and Pharmacodynamics of Midazolam Gel After Rectal Administration in Healthy Chinese Subjects
Background and ObjectivesMidazolam rectal gel is a novel rectal formulation that may be a promising and potential alternative to oral administration...
-
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
Fostamatinib is the first approved spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia. This review summarizes the clinical...
-
Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment
BackgroundJanagliflozin is a novel sodium–glucose cotransport-2 inhibitor. Despite its remarkable effect in glycemic control, no systematic research...
-
Pharmacokinetics and pharmacodynamics of bioactive compounds in Penyanqing preparation in THP-1 inflammatory cells induced by Lipopolysaccharide
BackgroundPenyanqing (PYQ), a traditional Chinese medicine (TCM), has a good clinical efficacy for the treatment of pelvic inflammatory disease...
-
Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function
ObjectiveHSK7653 is a novel, ultralong-acting dipeptidyl peptidase-4 (DPP-4) inhibitor, promising for type 2 diabetes mellitus with a dosing regimen...
-
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
The pharmacokinetics of roxadustat are well characterized, with an apparent volume of distribution after oral administration of 22–57 L, apparent...
-
Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
Background and ObjectiveThe search for potential gene loci that affect the pharmacodynamics and pharmacokinetics of ticagrelor is a matter of broad...
-
Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide
PurposeTo assess the pharmacokinetics, pharmacodynamics, safety and tolerability of subcutaneous depot CAM4071, a novel, ready-to-use pasireotide...
-
Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist
BackgroundASC42 is a non-steroidal farnesoid X receptor agonist currently in clinical development for chronic liver diseases, such as nonalcoholic...
-
Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges
Polypharmacy is commonly employed in clinical settings. The potential risks of drug–drug interactions (DDIs) can compromise efficacy and pose serious...
